Edoxaban

Pronunciation: eh-DOX-a-ban.

Generic name
edoxaban
Drug class
Direct factor Xa inhibitor (oral anticoagulant / "blood thinner")
Form
Tablet (15 mg, 30 mg, 60 mg)
Route
Oral
Legal status
Prescription-only

Availability and supply rules vary by country

Trade names by country: United States · United Kingdom · Canada

Australia: · Full directory

What edoxaban is and how it works

Edoxaban is a once-daily oral anticoagulant (blood thinner) that directly blocks factor Xa, a protein the body needs to form blood clots. It is used to lower the risk of stroke in people with nonvalvular atrial fibrillation (an irregular heart rhythm), and to treat blood clots in the legs (deep vein thrombosis) or lungs (pulmonary embolism) after initial treatment with an injectable blood thinner. (1)

Edoxaban carries a genuinely unusual FDA boxed warning: for the atrial fibrillation use, it should not be used in people whose kidneys clear it too quickly (creatinine clearance above 95 mL/min), because it does not work as well in that situation -- the opposite of the more familiar 'reduce the dose in kidney disease' pattern. It also should never be stopped without a plan to cover the gap with another anticoagulant, and it carries a real risk of dangerous bleeding around the spinal cord if spinal anesthesia or a spinal procedure is needed. Anyone considering or taking edoxaban should discuss all of this with their prescriber.

Mechanism of action: how edoxaban works

Edoxaban is a direct, selective, reversible inhibitor of activated coagulation factor Xa (FXa), blocking the intrinsic and extrinsic pathways of the coagulation cascade at the point of thrombin generation, without requiring a cofactor such as antithrombin III. (1) (2)

What edoxaban is used for

Stroke and systemic embolism prevention in nonvalvular atrial fibrillation

Used to reduce the risk of stroke and blood clots travelling elsewhere in the body (systemic embolism) in adults with nonvalvular atrial fibrillation, generally in people with a creatinine clearance of 95 mL/min or below. (1) (2)

Deep vein thrombosis (DVT) and pulmonary embolism (PE)

Used to treat DVT and PE after 5-10 days of initial treatment with an injectable (parenteral) anticoagulant, and to help prevent these clots from recurring. (1) (4)

Before taking edoxaban

Do not take / not appropriate for

  • Do not take edoxaban if you have active, clinically significant bleeding. (all countries) (1) (2)
  • For the atrial fibrillation use specifically, edoxaban should not be used if your creatinine clearance is above 95 mL/min -- your clinician will test your kidney function before prescribing it for this reason. (United States (FDA boxed-warning restriction); framed as a caution requiring individualised risk assessment, not an absolute restriction, in the UK/EU label) (1) (2)
  • Do not take edoxaban if your kidneys have essentially stopped working (creatinine clearance below 15 mL/min). (all countries) (2)
  • Do not take edoxaban if you have liver disease with a bleeding tendency, or a known condition with a high risk of major bleeding (such as a current stomach ulcer or a history of bleeding in the brain). (United Kingdom, European Union) (2)
  • Do not take edoxaban together with another anticoagulant medicine, except during a supervised switch from one to the other. (all countries) (2)
  • Do not take edoxaban if you are pregnant or breastfeeding. (United Kingdom, European Union) (2)

Tell your clinician about

  • Your kidney function (creatinine clearance) -- this determines your dose, and for the atrial fibrillation use, whether edoxaban is appropriate for you at all.
  • Any history of bleeding problems, stomach ulcers, or bleeding in the brain.
  • Any planned surgery, dental work, or spinal/epidural procedure -- edoxaban may need to be stopped temporarily, and spinal procedures carry a specific bleeding risk described in the boxed warning.
  • All other medicines, especially other anticoagulants, antiplatelet medicines (like aspirin or clopidogrel), or regular NSAID painkillers, which increase bleeding risk.
  • Any liver problems.
  • Whether you are pregnant, could become pregnant, or are breastfeeding.
(1) (2)

How to take edoxaban

  • Taken once daily, with or without food, at the same time each day.
  • Swallow tablets whole; if you cannot swallow whole tablets, ask your pharmacist about crushing options.
  • Never stop taking edoxaban on your own without talking to your clinician first -- stopping without a plan for alternative anticoagulation raises the risk of stroke or other clot-related events.
  • If you need surgery, dental work, or a spinal procedure, tell the treating team you take edoxaban well in advance, so they can advise on timing.
(1) (2)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6)

Missed dose

Take the missed dose as soon as you remember on the same day, then resume your normal once-daily schedule the next day. Do not take a double dose to make up for a missed one. Contact your clinician or pharmacist if you are unsure what to do.

Overdose

Seek urgent medical attention if you think you have taken too much edoxaban, or if you notice any signs of bleeding (such as unusual bruising, blood in urine or stool, prolonged bleeding from a cut, or severe headache). There is no specific reversal agent broadly available for edoxaban in the way there is for some other anticoagulants; management is supportive and may include activated charcoal if given soon after an overdose. (1)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Bleeding, including nosebleeds, bruising, and heavier or longer menstrual bleeding.

What to notice: Bleeding, including nosebleeds, bruising, and heavier or longer menstrual bleeding.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2)

Anaemia (low red blood cell count), reported more often than with warfarin in long-term use.

What to notice: Anaemia (low red blood cell count), reported more often than with warfarin in long-term use.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2)

Rash.

What to notice: Rash.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2)

Abnormal liver blood test results.

What to notice: Abnormal liver blood test results.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2)

Serious warnings

Very high kidney function reducing effectiveness (atrial fibrillation use) — boxed_warning

Symptoms: Not a symptom-based warning -- this is a lab-based restriction identified before treatment starts.

Action: Your clinician tests your kidney function (creatinine clearance) before starting edoxaban for atrial fibrillation. In the US, edoxaban should not be used for this indication if your creatinine clearance is above 95 mL/min, because trial data showed a higher stroke rate in this group compared with warfarin. Ask your clinician which framing applies to your care. (1)

Signs of a blood clot or stroke after stopping edoxaban — boxed_warning

Symptoms: Sudden weakness or numbness (especially on one side of the body), trouble speaking, vision changes, sudden severe headache, chest pain, or shortness of breath.

Action: Seek emergency medical help immediately. Never stop taking edoxaban without first discussing an alternative anticoagulation plan with your clinician -- stopping abruptly increases the risk of stroke and other clot-related events. (1)

Signs of spinal or epidural bleeding after spinal anesthesia or a spinal procedure — boxed_warning

Symptoms: New back pain, tingling, numbness, muscle weakness in the legs, or loss of bladder or bowel control after spinal/epidural anesthesia or a spinal tap.

Action: Seek emergency medical help immediately -- this can signal bleeding around the spinal cord (spinal/epidural hematoma), which can cause long-term or permanent paralysis if not treated promptly. (1)

Signs of serious bleeding — high caution

Symptoms: Blood in urine or stool, black or tarry stools, coughing up blood, vomiting blood, unusual or severe bruising, or a headache that will not go away.

Action: Contact your clinician promptly or seek emergency care -- edoxaban can cause serious, potentially fatal bleeding. (2)

Interactions

  • Rifampin substantially reduces edoxaban's effect and should generally be avoided. (1)
  • Ciclosporin, dronedarone, erythromycin, and ketoconazole (P-glycoprotein inhibitors) raise edoxaban levels and require the lower 30 mg dose for the DVT/PE indication. (2)
  • Amiodarone, quinidine, and verapamil raise edoxaban levels but do not require a dose reduction in most cases. (2)
  • Other anticoagulants, antiplatelet medicines (such as aspirin or clopidogrel), and regular NSAID use increase bleeding risk when combined with edoxaban. (2) (1)
  • SSRIs and SNRIs (certain antidepressants) may add to bleeding risk when combined with edoxaban. (1)

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

Not recommended in pregnancy in the sources reviewed (contraindicated in the UK/EU label); discuss family planning with your clinician before starting. (1) (2) (3) (4) (5) (6)

Children

Safety and effectiveness in children under 18 have not been established; not recommended in this age group. (1) (2) (3) (4) (5) (6)

Elderly

No separate dose adjustment is made for age alone, but bleeding risk should be weighed carefully, and kidney function (which affects dosing) is often lower in older adults. (1) (2) (3) (4) (5) (6)

Hepatic_impairment

Not recommended in moderate-to-severe liver impairment, or in any liver disease associated with a bleeding tendency; use with caution in mild impairment. (1) (2) (3) (4) (5) (6)

Renal_impairment

Dose is adjusted based on creatinine clearance; contraindicated at CrCl <15 mL/min; for the atrial fibrillation use specifically, the US label restricts use above CrCl 95 mL/min, while the UK/EU label calls for individualised risk assessment instead. (1) (2) (3) (4) (5) (6)

Monitoring

Before starting

  • Kidney function (creatinine clearance, via the Cockcroft-Gault formula)
  • Liver function tests
  • Baseline full blood count
  • Review of other medicines for bleeding-risk or P-gp interactions

During treatment

  • Periodic reassessment of kidney function, particularly if it could change (e.g. acute illness, new interacting medicines).
  • Prompt evaluation of any signs or symptoms of bleeding.
  • Careful planning around any surgery, dental work, or spinal/epidural procedure.
(2) (1)

Storage

Store tablets at room temperature in their original packaging, protected from moisture, out of reach of children.

Study the drug class: Direct oral anticoagulants

Professional information

Clinician-facing context only, sourced from the current US FDA prescribing information and UK SmPC for edoxaban; verify against the current full label before prescribing.

United States

Indication: Nonvalvular atrial fibrillation

Dose summary: 60 mg once daily if CrCL >50 to <=95 mL/min; 30 mg once daily if CrCL 15-50 mL/min; should not be used per the boxed warning if CrCL >95 mL/min.

Renal context: Boxed-warning restriction against use above CrCL 95 mL/min for this indication specifically, based on ENGAGE AF-TIMI 48 trial data showing increased ischemic stroke versus warfarin at that renal-function level. (1)

United Kingdom / European Union

Indication: Nonvalvular atrial fibrillation

Dose summary: 60 mg once daily standard dose, 30 mg once daily if CrCl 15-50 mL/min, weight <=60 kg, or specific P-gp inhibitor use.

Renal context: High CrCl is framed as requiring individualised thromboembolic/bleeding risk assessment rather than an absolute restriction -- a genuine difference from the US label's boxed-warning restriction. (2)

Canada

Indication: Nonvalvular atrial fibrillation and DVT/PE

Dose summary: 60 mg once daily standard dose, reduced to 30 mg once daily for CrCL 30-50 mL/min, weight <=60 kg, or specific P-gp inhibitors other than amiodarone (verapamil, quinidine, dronedarone).

Renal context: Health Canada's Serious Warnings and Precautions box centres on bleeding risk and discontinuation-related thrombotic risk; it does not carry the US label's specific CrCL>95 restriction. (4)

Mechanism of action

Hepatic guidance

Not recommended in moderate-to-severe hepatic impairment or in any hepatic disease associated with coagulopathy and clinically relevant bleeding risk.

Overdose note

No specific, broadly available reversal agent; manage supportively, consider activated charcoal if given soon after ingestion, and consider hemostatic measures for active bleeding. (1) (2)

Frequently asked questions

Why does edoxaban have a warning about kidneys working too well?

This is a genuinely unusual part of edoxaban's FDA boxed warning. For the atrial fibrillation use, a large clinical trial (ENGAGE AF-TIMI 48) found that people whose kidneys cleared creatinine faster than 95 mL/min had more strokes on edoxaban than on warfarin -- the opposite direction from the more familiar concern that poor kidney function makes a drug build up. Because of this, the US label says edoxaban should not be used for this indication above that kidney-function level, and kidney function is tested before starting treatment. The UK/EU label instead asks prescribers to weigh the individual risks and benefits carefully in this situation, rather than ruling it out entirely. (1) (2)

Can I just stop taking edoxaban if I feel fine?

No. Stopping edoxaban (or any oral anticoagulant) without a plan to cover the gap with another anticoagulant increases the risk of stroke and other blood clot-related events -- this is one of the three parts of the FDA's boxed warning for edoxaban. Always talk to your clinician before stopping, unless you are told to stop because of active bleeding. (1)

Is edoxaban available in the US, UK, Europe, Canada, Australia, and New Zealand?

It is authorised in the United States (as Savaysa), the United Kingdom, the European Union, and Canada (as Lixiana, including generic versions in Canada). It is NOT approved in Australia -- confirmed by a peer-reviewed study comparing DOAC approvals across major regulators, which found edoxaban is the only one of the four major direct oral anticoagulants without Australian TGA approval. It also does not appear to be available in New Zealand, based on consistent New Zealand prescribing and funding sources, though this could not be confirmed directly against a primary Medsafe register entry in this review. (1) (2) (3) (4) (5) (6)

What if I need spinal anesthesia or a spinal tap while on edoxaban?

Tell every member of your care team that you take edoxaban well before any planned procedure. Spinal or epidural anesthesia, and spinal taps, carry a specific risk of bleeding around the spinal cord in people taking edoxaban, which is part of its FDA boxed warning and can cause long-term or permanent paralysis if not caught and treated quickly. Report any new back pain, numbness, tingling, leg weakness, or loss of bladder/bowel control immediately after such a procedure. (1)

What is the mechanism of action of edoxaban?

Edoxaban is a direct, selective, reversible inhibitor of activated coagulation factor Xa (FXa), blocking the intrinsic and extrinsic pathways of the coagulation cascade at the point of thrombin generation, without requiring a cofactor such as antithrombin III. (1) (2)

What is the generic name of Edoxaban?

The generic name is edoxaban. (1) (2) (3) (4)

What class of drug is edoxaban?

Edoxaban is classed as: Direct factor Xa inhibitor (oral anticoagulant / "blood thinner"). (1) (2) (3) (4)

References

  1. SAVAYSA (edoxaban tosylate) tablets, film coated -- full prescribing informationU.S. Food and Drug Administration / DailyMed (NIH), full prescribing information, Daiichi Sankyo, Inc. · United States · accessed 2026-07-30 · source 1
  2. Lixiana 60 mg Film-Coated Tablets -- Summary of Product Characteristicselectronic medicines compendium (emc), United Kingdom -- Daiichi Sankyo UK Ltd · United Kingdom · accessed 2026-07-30 · source 2
  3. Lixiana (edoxaban) -- EPAR medicine overviewEuropean Medicines Agency (EMA) -- EPAR medicine overview for Lixiana · European Union · accessed 2026-07-30 · source 3
  4. LIXIANA (edoxaban) Product Monograph, and generic edoxaban product monographsHealth Canada product monograph, Servier Canada Inc. (brand); generic product monographs also on file (Pro-Edoxaban, Teva-Edoxaban, GLN-Edoxaban) · Canada · accessed 2026-07-30 · source 4
  5. Direct oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidencePeer-reviewed cross-sectional regulatory-comparison study (BMJ Open), corroborating the absence of any Therapeutic Goods Administration (TGA) / Australian Register of Therapeutic Goods (ARTG) entry for edoxaban · Australia · accessed 2026-07-30 · source 5
  6. Oral anticoagulant selection in primary care (bpac.org.nz, 2023) and related PHARMAC/Medsafe anticoagulant materialsBest Practice Advocacy Centre New Zealand (bpac.org.nz) prescriber guidance, cross-checked against PHARMAC funding decisions and Medsafe Medicines Adverse Reactions Committee (MARC) anticoagulant reports · New Zealand · accessed 2026-07-30 · source 6

Brand names by country

Single-ingredient edoxaban names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries

United States

  • SAVAYSA30 mg, 60 mg, 15 mg · daiichi sankyo inc.

United Kingdom

  • Lixiana (2)MHRA licensed emc smpc confirmed · 15 mg, 30 mg, 60 mg · Daiichi Sankyo UK Ltd

Canada

  • LIXIANA
View brands in additional countries.

European Union

Lixiana (3)

This page provides general reference information about edoxaban and is not a substitute for advice from your prescriber. All dosing, monitoring, and treatment decisions -- including whether edoxaban is appropriate given your kidney function -- should be made with the clinician managing your care.

Related medicines